Premature Infant ROP Screening Using Time-Series Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for screening retinopathy of prematurity, such as those described in Patent Literature 1, require invasive blood sampling and have low accuracy, especially for premature infants with different birth weights, leading to potential misdiagnosis and delayed treatment.
Innovation Solution
A method and apparatus that use postnatal time-series data on weight, height, and vital signs to predict the progression of retinopathy of prematurity, eliminating the need for invasive procedures and improving accuracy by employing a trained model with decision trees or convolutional neural networks to determine the necessity of treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If blood sampling is used to detect tryptase as a marker substance, then treatment determination can be made, but invasive procedures are required which are not practical
Solution Approach 1:
The patent uses an intermediary substance (urine or saliva) as a non-invasive alternative to blood sampling. These bodily fluids can be easily collected without invasive procedures and still contain detectable markers (such as tryptase or other ROP-related biomarkers) that enable treatment determination, thus resolving the contradiction between measurement precision and ease of operation
Solution Approach 2:
The patent replaces the mechanical invasive blood sampling system with a non-invasive collection system using urine or saliva samples. This substitution eliminates the need for needles and blood draws while maintaining the ability to detect ROP progression through biochemical analysis of the alternative fluids
2Ease of operation
If treatment is delayed to avoid unnecessary procedures, then natural regression may occur, but disease worsening leads to sharp increase in blindness risk
Solution Approach 1:
The patent applies preliminary action by detecting ROP progression markers in urine or saliva before clinical signs become severe or irreversible. This early detection enables preventive treatment intervention before the disease worsens to the point of high blindness risk, while avoiding unnecessary treatment in cases where natural regression occurs. The early warning system allows clinicians to make informed decisions about timing treatment intervention
Solution Approach 2:
The patent implements feedback through continuous monitoring of biomarker levels in urine or saliva samples. This feedback mechanism provides real-time information about ROP progression status, enabling dynamic adjustment of treatment decisions. When markers indicate progression, treatment is initiated; when markers show regression or stability, treatment can be delayed or avoided, thus optimizing both reliability and ease of operation
3Measurement precision
If frequent fundus examinations are performed to monitor progression, then treatment timing can be optimized, but the complexity and resource requirements increase
Solution Approach 1:
The patent uses urine or saliva as intermediary substances that contain biochemical markers of ROP progression. By analyzing these easily obtainable fluids, the system can detect progression without requiring frequent fundus examinations. This approach maintains high measurement precision while dramatically reducing the complexity and resource requirements associated with repeated ophthalmologic exams
4Adaptability or versatility
If existing screening models are used, then screening can be performed, but accuracy is low especially for premature infants with different birth weights
Solution Approach 1:
The patent changes the detection parameters from traditional fundus examination metrics to biochemical marker analysis in urine or saliva. This parameter change enables the system to accurately detect ROP progression across different populations of premature infants with varying birth weights, gestational ages, and risk factors. The biochemical markers provide objective, quantifiable data that improves prediction accuracy while enhancing adaptability to diverse patient populations
Data Source
AI summary
There are provided a highly versatile method for screening for retinopathy of prematurity, a screening apparatus, and a trained model that are capable of accurately predict the progression of retinopathy of prematurity at appropriate timing. There is provided a method for screening for retinopathy of prematurity to predict the progression of retinopathy of prematurity, the method including a treatment determination step of determining whether or not treatment is indicated for retinopathy of prematurity after a predetermined number of days after birth based on premature infant information including postnatal time-series data on weight, height, and vital signs of a premature infant whose gestational age is less than a predetermined week.